Equities Analysts Issue Forecasts for TLSI Q3 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for TriSalus Life Sciences in a note issued to investors on Wednesday, September 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.14) for the quarter, down from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for TriSalus Life Sciences’ Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.53) EPS.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Guggenheim set a $12.00 price target on TriSalus Life Sciences in a research report on Wednesday. Zacks Research upgraded TriSalus Life Sciences to a “hold” rating in a report on Thursday, September 10th. Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Wednesday. Finally, Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.20.

TriSalus Life Sciences Stock Down 7.8%

TriSalus Life Sciences stock opened at $4.61 on Friday. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The firm has a fifty day moving average price of $4.90 and a two-hundred day moving average price of $4.32. The firm has a market cap of $283.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.44.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to the consensus estimate of $10.27 million.

Institutional Trading of TriSalus Life Sciences

Several hedge funds have recently modified their holdings of the stock. State Street Corp lifted its holdings in TriSalus Life Sciences by 86.3% during the 2nd quarter. State Street Corp now owns 610,963 shares of the company’s stock worth $2,780,000 after buying an additional 282,943 shares in the last quarter. First Light Asset Management LLC raised its position in shares of TriSalus Life Sciences by 29.3% during the second quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock worth $29,814,000 after acquiring an additional 1,485,664 shares during the last quarter. Corient Private Wealth LP raised its position in shares of TriSalus Life Sciences by 61.7% during the second quarter. Corient Private Wealth LP now owns 147,152 shares of the company’s stock worth $670,000 after acquiring an additional 56,152 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of TriSalus Life Sciences during the second quarter valued at $4,550,000. Finally, Bank of America Corp DE bought a new position in TriSalus Life Sciences in the second quarter valued at about $934,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences News Roundup

Here are the key news stories impacting TriSalus Life Sciences this week:

• Positive Sentiment: FDA clearance for TriNav Advance, a device intended for liver embolization procedures, strengthens TriSalus’s product portfolio and could support future adoption, revenue growth and commercial momentum. The shares rose substantially following the announcement. TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance
• Positive Sentiment: HC Wainwright raised its price target for TLSI to $12 from $11 and maintained a “Buy” rating. The new target implies substantial upside from the reference price and reinforces the bullish case among some analysts.
• Positive Sentiment: The FDA decision generated notable investor interest and elevated trading activity, suggesting that the regulatory milestone is currently the main explanation for the stock’s upward move. Update: TriSalus Life Sciences Shares Rise After Receiving FDA Clearance for TriNav Advance

About TriSalus Life Sciences

TriSalus Life Sciences is an oncology company focused on developing technologies and therapies for patients with liver and pancreatic tumors. The company’s approach combines investigational immunotherapies with drug-delivery technologies intended to improve treatment access to solid tumors, which can be difficult to reach through conventional systemic administration.

TriSalus is best known for its Pressure-Enabled Drug Delivery (PEDD) platform, which is designed to deliver medicines directly into tumors or their surrounding blood vessels by using controlled pressure.